Grifols
Note: This is a daily stock update and the information stands true as of 13/05/25, 09:00 CET.
Company Update:
Expert Opinion:
Grifols ADR were up 9% yesterday. Despite the share price fall, our expert remains convinced of the underlying quality of the company. Its products are good and sell very well. Its balance sheet is improving and we believe there will be no capital increase. The massive drop in share price following the Gotham research report is an opportunity to buy the stock and wait for the normalization. Stock used to trade with a PE around 20x. It now trades on PE25 and 26 of 8.2x and 6.6x respectively, for a company that is arguably in a much better shape today than it was a few years back.
For daily updates, subscribe to our newsletter and for detailed information, reach out to us at sales@alphavalue.eu
Company Update:
Q1 sales came in up 10% at €1.8bn (7.4% lfl).
'Adjusted' EBITDA jumped c.14% to €400m, supported by operating leverage and cost savings.
Deleveraging continued, with 'reported' leverage ratio improving to 5.5x at end-Q1 25 vs. 5.6x at end-Q4 24.
2025 Guidance maintained: Sales and 'adjusted' EBITDA are expected in the range of €7.5-7.6bn and €1.875-1.925bn, respectively. Also, FCF of €350-400m is targeted in 2025 (vs. €266m in 2024).
Grifols ADR were up 9% yesterday. Despite the share price fall, our expert remains convinced of the underlying quality of the company. Its products are good and sell very well. Its balance sheet is improving and we believe there will be no capital increase. The massive drop in share price following the Gotham research report is an opportunity to buy the stock and wait for the normalization. Stock used to trade with a PE around 20x. It now trades on PE25 and 26 of 8.2x and 6.6x respectively, for a company that is arguably in a much better shape today than it was a few years back.
For daily updates, subscribe to our newsletter and for detailed information, reach out to us at sales@alphavalue.eu
Subscribe to our blog
Alphavalue Morning Market Tip
Beat in Q1 but Wegovy sales are below expectations. FY25 sales guidance downgraded.
Alphavalue Morning Market Tip
Very strong Q1 but FY guidance lowered due to tariffs impact.